Aussie Oncologists Say Trial Trend Makes Treatments Costlier
This article was originally published in PharmAsia News
Australian oncologists are calling for independent research of cancer drugs to guard against overuse of expensive ones and those more toxic. The physicians wrote in a professional journal that clinical trials have shifted to testing how long drugs could be tolerated and away from using them until maximum response is determined and then halting their use to avoid toxicity. Their article in The Medical Journal of Australia said that shift toward longer use is not supported by survival or quality-of-life data, making treatment potentially much costlier. (Click here for more
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.